Our Pipeline
We have made considerable progress with our branded and generic product development
activities. Focusing on our proprietary drug delivery technology expertise and core
therapeutic categories, we continue to review strategic additions to our branded
and generic product pipelines.
Watson Brands Product Pipeline Status
| Branded Product | Disease/Market | Alliance | Status |
|---|
| Silodosin | Benign-Prostatic Hyperplasia/Urology | Kissei | Late Stage |
| Oxybutynin Gel | Overactive Bladder/Urology | - | Late Stage |
| Trelstar® line extension | Advanced Prostate Cancer/Urology | Debiopharm | Late Stage |
| URACYST® | Interstitial cystitis | Stellar | Phase I |
Watson Generics Product Pipeline Status
